Milestones in breast cancer treatment

Breast Journal

Volumn 21, Issue 1, 2015, Pages 3-12

  Zurrida, Stefano ^a   Veronesi, Umberto ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

breast cancer; breast conserving surgery; chemotherapy; external beam whole breast irradiation; intraoperative radiotherapy; radioguided occult lesion localization; sentinel node biopsy; tamoxifen; targeted therapies

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; FLUOROURACIL; METHOTREXATE; PERTUZUMAB; TAMOXIFEN; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

ARTICLE; BREAST CANCER; BREAST LESION; BREAST RECONSTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CONSERVATIVE TREATMENT; EXTERNAL BEAM RADIOTHERAPY; HUMAN; INTRAOPERATIVE RADIOTHERAPY; MAMMOGRAPHY; MASTECTOMY; META ANALYSIS (TOPIC); MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PARTIAL MASTECTOMY; PHASE 3 CLINICAL TRIAL (TOPIC); RADIOGUIDED OCCULT LESION LOCALIZATION; RADIOISOTOPE THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENTINEL LYMPH NODE BIOPSY; SURGICAL APPROACH; SURGICAL TECHNIQUE; TREATMENT DURATION; ADJUVANT THERAPY; BREAST NEOPLASMS; FEMALE; HISTORY; PROCEDURES;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HISTORY, ANCIENT; HUMANS; MASTECTOMY; RADIOTHERAPY, ADJUVANT; SENTINEL LYMPH NODE BIOPSY;

EID: 84920917963     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/tbj.12361     Document Type: Article

References (79)

1. Breasted JH,. The Edwin Smith Surgical Papyrus. Translation for The New York Historical Society. Chicago, IL: University of Chicago Press, 1930.
2. Veronesi U, Saccozzi R, Del Vecchio M, et al,. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med 1981; 305: 6-11.
3. Veronesi U, Volterrani F, Luini A, et al,. Quadrantectomy versus lumpectomy for small size breast cancer. Eur J Cancer 1990; 26: 671-3.
4. Veronesi U, Luini A, Del Vecchio M, et al,. Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med 1992; 328: 1587-91.
5. Veronesi U, Cascinelli N, Mariani L, et al,. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002; 347: 1227-32.
6. Fisher B, Bauer M, Margolese R, et al,. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 1985; 312: 665-73.
7. Treatment of Early-Stage Breast Cancer. NIH Consensus Statement Available at: http://consensus.nih.gov/1990/1990earlystagebreastcancer081html.html. Published June, 1990.
8. Freedman RA, He Y, Winer EP, et al,. Trends in racial and age disparities in definitive local therapy of early-stage breast cancer. J Clin Oncol 2009; 27: 713-9.
9. Garcia-Etienne CA, Tomatis M, Heil J, et al,. Mastectomy trends for early-stage breast cancer: a report from the EUSOMA multi-institutional European database. Eur J Cancer 2012; 48: 1947-56.
10. Veronesi U, Luini A, Galimberti V, Marchini S, Sacchini V, Rilke F,. Extent of metastatic axillary involvement in 1446 cases of breast cancer. Eur J Surg Oncol 1990; 16: 127-33.
11. Fisher B, Montague E, Redmond C, et al,. Comparison of radical mastectomy with alternative treatments for primary breast cancer. A first report of results from a prospective randomized clinical trial. Cancer 1977; 39 (6 Suppl): 2827-39.
12. Mandelblatt JS, Edge SB, Meropol NJ, et al,. Sequelae of axillary lymph node dissection in older women with stage 1 and 2 breast carcinoma. Cancer 2002; 95: 2445-54.
13. Kuehn T, Klauss W, Darsow M, et al,. Long-term morbidity following axillary dissection in breast cancer patients-clinical assessment, significance for life quality and the impact of demographic, oncologic and therapeutic factors. Breast Cancer Res Treat 2000; 64: 275-86.
14. Krag DN, Weaver DL, Alex JC, et al,. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993; 2: 335-9.
15. Giuliano AE, Dale PS, Turner RR, et al,. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995; 222: 394-401.
16. Veronesi U, Paganelli G, Viale G, et al,. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003; 349: 546-53.
17. Veronesi U, Viale G, Paganelli G, et al,. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg 2010; 251: 595-600.
18. Lyman GH, Temin S, Edge SB, et al,. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2014; 32: 1365-83.
19. Galimberti V, Cole BF, Zurrida S, et al,. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 2013; 14: 297-305.
20. Giuliano AE, Hunt KK, Ballman KV, et al,. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis. JAMA 2011; 305: 569-75.
21. Giuliano AE, Morrow M, Duggal S, Julian TB,. Should ACOSOG Z0011 change practice with respect to axillary lymph node dissection for a positive sentinel lymph node biopsy in breast cancer? Clin Exp Metastasis 2012; 29: 687-92.
22. Gentilini O, Veronesi U,. Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: sentinel node vs observation after axillary UltraSouND). Breast 2012; 21: 678-81.
23. Veronesi U, Luini A, Botteri E, et al,. Nonpalpable breast carcinomas: long-term evaluation of 1,258 cases. Oncologist 2010; 15: 1248-52.
24. Verbeek AL,. Mammographic screening: keeping women alive. Womens Health (Lond Engl) 2011; 7: 631-3.
25. http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx (accessed November 2014).
26. Kelly KM, Dean J, Lee SJ, Comulada WS,. Breast cancer detection: radiologists' performance using mammography with and without automated whole-breast ultrasound. Eur Radiol 2010; 20: 2557-64.
27. Nadeem R, Chagla LS, Harris O, et al,. Occult breast lesions: a comparison between radioguided occult lesion localisation (ROLL) vs. wire-guided lumpectomy (WGL). Breast 2005; 14: 283-9.
28. Luini A, Zurrida S, Paganelli G, et al,. Comparison of radioguided excision with wire localization of occult breast lesions. Br J Surg 1999; 86: 522-5.
29. Monti S, Galimberti V, Trifirò G, et al,. Occult breast lesion localization plus sentinel node biopsy (SNOLL): experience with 959 patients at the European Institute of Oncology. Ann Surg Oncol 2007; 14: 2928-31.
30. Giacalone PL, Bourdon A, Trinh PD, et al,. Radioguided occult lesion localization plus sentinel node biopsy (SNOLL) versus wire-guided localization plus sentinel node detection: a case control study of 129 unifocal pure invasive non-palpable breast cancer. Eur J Surg Oncol 2012; 38: 222-9.
31. Morrow M, Jagsi R, Alderman A, et al,. Surgeon recommendations and receipt of mastectomy for treatment of breast cancer. JAMA 2009; 302: 1551-6.
32. Boneti C, Yuen J, Santiago C, et al,. Oncologic safety of nipple skin-sparing or total skin-sparing mastectomies with immediate reconstruction. Ann Surg Oncol 2010; 17 (Suppl 3): 378-83.
33. Yi M, Kronowitz SJ, Meric-Bernstam F, et al,. Local, regional and systemic recurrence rates in patients undergoing skin-sparing mastectomy compared with conventional mastectomy. Cancer 2011; 117: 916-24.
34. Petit JY, Gentilini O, Rotmensz N, et al,. Oncological results of immediate breast reconstruction: long term follow-up of a large series at a single institution. Breast Cancer Res Treat 2008; 112: 545-9.
35. Giacalone PL, Rathat G, Daures JP, et al,. New concept for immediate breast reconstruction for invasive cancers: feasibility, oncological safety and esthetic outcome of post-neoadjuvant therapy immediate breast reconstruction versus delayed breast reconstruction: a prospective pilot study. Breast Cancer Res Treat 2010; 122: 439-51.
36. Petit JY, Veronesi U, Orecchia R, et al,. Nipple sparing mastectomy with nipple areola intraoperative radiotherapy: one thousand and one cases of a five years experience at European Institute of Oncology of Milan (EIO). Breast Cancer Res Treat 2009; 117: 333-8.
37. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, et al,. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet 2011; 378: 1707-16.
38. START Trialists' Group, Bentzen SM, Agrawal RK, et al,. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008; 371: 1098-107.
39. Whelan TJ, Pignol JP, Levine MN, et al,. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010; 362: 513-20.
40. Verellen D, De Ridder M, Linthout N, et al,. Innovations in image-guided radiotherapy. Nat Rev Cancer 2007; 7: 949-60.
41. Barnett GC, Wilkinson JS, Moody AM, et al,. Randomized controlled trial of forward-planned intensity-modulated radiotherapy for early breast cancer: interim results at 2 years. Int J Radiat Oncol Biol Phys 2012; 82: 715-23.
42. Donovan E, Bleakley N, Denholm E, et al,. Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol 2007; 82: 254-64.
43. Pignol JP, Olivotto I, Rakovitch E, et al,. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol 2008; 26: 2085-92.
44. Smith BD, Pan I-W, Shih Y-C, et al,. Adoption of intensity-modulated radiation therapy for breast cancer in the United States. J Natl Cancer Inst 2011; 103: 798-809.
45. Veronesi U, Marubini E, Mariani L, et al,. Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol 2001; 12: 997-1003.
46. Vaidya JS, Vyas JJ, Chinoy RF, et al,. Multicentricity of breast cancer: whole-organ analysis and clinical implications. Br J Cancer 1996; 74: 820-4.
47. Veronesi U, Orecchia R, Luini A, et al,. Intraoperative radiotherapy during breast conserving surgery: a study on 1,822 cases treated with electrons. Breast Cancer Res Treat 2010; 124: 141-51.
48. Veronesi U, Orecchia R, Maisonneuve P, et al,. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol 2013; 14: 1269-77.
49. Bartelink H, Horiot JC, Poortmans R, European Organization for Research and Treatment of Cancer Radiotherapy and Breast Cancer Groups, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001; 345: 1378-87.
50. Polgar C, Fodor J, Orosz Z, et al,. Electron and high-dose-rate brachytherapy boost in the conservative treatment of stage l-ll breast cancer first results of the randomized Budapest boost trial. Stralenther Onkol 2002; 178: 615-23.
51. Romestaing P, Lehingue Y, Carrie C, et al,. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol 1997; 15: 963-8.
52. Fastner G, Sedlmayer F, Merz F, et al,. IORT with electrons as boost strategy during breast conserving therapy in limited stage breast cancer: long term results of an ISIORT pooled analysis. Radiother Oncol 2013; 108: 279-86.
53. Ivaldi GB, Leonardi MC, Orecchia R, et al,. Preliminary results of electron intraoperative therapy boost and hypofractionated external beam radiotherapy after breast-conserving surgery in premenopausal women. Int J Radiat Oncol Biol Phys 2008; 72: 485-93.
54. http://www.clinicaltrials.gov/ct2/show/NCT01343459?term=hiob&rank=1
55. Cole MP, Jones CT, Todd ID,. A new anti-estrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer 1971; 25: 270-5.
56. Baum M, Brinkley DM, Dossett JA, et al,. Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet 1983; 2: 450.
57. Furr BJ, Jordan VC,. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 1984; 25: 127-205.
58. Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998; 351: 1451-61.
59. Burstein HJ, Temin S, Anderson H, et al,. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol 2014; 32: 2255-69.
60. Pagani O, Regan MM, Walley BA, et al,. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014; 371: 107-18.
61. Jordan VC,. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov 2003; 2: 205-13.
62. Vogel VG, Costantino JP, Wickerham DL, et al,. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila) 2010; 3: 696-706.
63. DeVita VT Jr, Chu E,. A history of cancer chemotherapy. Cancer Res 2008; 68: 8643-53.
64. Rossi A, Bonadonna G, Valagussa P, Veronesi U,. Multimodal treatment in operable breast cancer: five-year results of the CMF programme. Br Med J (Clin Res Ed) 1981; 282: 1427-31.
65. Bonadonna G, Rossi A, Valagussa P,. Adjuvant CMF chemotherapy in operable breast cancer: ten years later. World J Surg 1985; 9: 707-13.
66. Early Breast Cancer Trialists' Collaborative Group. Multi-agent chemotherapy for early breast cancer. Cochrane Database Syst Rev 2002;(1): CD000487. Review.
67. Volkova M, Russell R 3rd,. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev 2011; 7: 214-20.
68. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998; 352: 930-42.
69. Goldhirsch A, Winer EP, Coates AS, et al,. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24: 2206-23.
70. Ellis MJ, Perou CM,. The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov 2013; 3: 27-34.
71. Ross JS, Fletcher JA,. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998; 16: 413-28.
72. Slamon D, Eiermann W, Robert N, et al,. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365: 1273-83.
73. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al,. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-72.
74. Pivot X, Romieu G, Debled M, et al,. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol 2013; 14: 741-8.
75. Baselga J, Cortés J, Kim S-B, et al,. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-19.
76. Swain S, Kim S, Ro J, et al,. Final overall survival (OS) analysis from the CLEOPATRA study of first-line (1L) pertuzumab (Ptz), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). European Society for Medical Oncology 2014. Abstract #350O-PR.
77. http://www.onclive.com/publications/oncology-business-news/2012/November-2012/Treatment-and-Cost-Implications-of-Pertuzumab
78. McGuire KP, Santillan AA, Kaur P, et al,. Are mastectomies on the rise? A 13-year trend analysis of the selection of mastectomy versus breast conservation therapy in 5865 patients. Ann Surg Oncol 2009; 16: 2682-90.
79. Mahmood U, Hanlon AL, Koshy M, et al,. Increasing national mastectomy rates for the treatment of early stage breast cancer. Ann Surg Oncol 2013; 20: 1436-43.